{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:30:06Z","timestamp":1793331006719,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2021.12.017","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:25:05Z","timestamp":1653553505000},"page":"S95-S102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"S1","title":["Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms"],"prefix":"10.1016","volume":"213","author":[{"given":"Despoina","family":"Pantazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.21037\/jtd.2017.02.75","article-title":"Cancer prevention from the perspective of global cancer burden patterns","volume":"9","author":"Nagai","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.thromres.2021.12.017_bb0010","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2021.12.017_bb0015","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.33963\/KP.15674","article-title":"Two professions against two killer diseases: the rationale, organization, and initial experience of a cardio-oncology service","volume":"79","author":"Tajstra","year":"2021","journal-title":"Kardiol. Pol."},{"issue":"18","key":"10.1016\/j.thromres.2021.12.017_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2021.12.017_bb0030","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719843435","article-title":"Cardiotoxicity due to targeted anticancer agents: a growing challenge","volume":"13","author":"Shah","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.thromres.2021.12.017_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0003319713498298","article-title":"Cardiotoxicity and cancer therapy","volume":"65","author":"Vasiliadis","year":"2014","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/cancers12030704","article-title":"MicroRNAs in cancer treatment-induced cardiotoxicity","volume":"12","author":"Pellegrini","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0305-7372(03)00116-6","article-title":"Classification of anticancer drugs--a new system based on therapeutic targets","volume":"29","author":"Espinosa","year":"2003","journal-title":"Cancer. Treat. Rev."},{"issue":"12","key":"10.1016\/j.thromres.2021.12.017_bb0050","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0060","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","article-title":"Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies","volume":"75","author":"Bonsu","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.thromres.2021.12.017_bb0065","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/jcm10081647","article-title":"Cancer therapy-related cardiovascular complications in clinical practice: current perspectives","volume":"10","author":"Bohdan","year":"2021","journal-title":"J. Clin. Med."},{"issue":"36","key":"10.1016\/j.thromres.2021.12.017_bb0070","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.thromres.2021.12.017_bb0075","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.seminoncol.2019.10.005","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology","volume":"46","author":"Breccia","year":"2019","journal-title":"Semin. Oncol."},{"issue":"11","key":"10.1016\/j.thromres.2021.12.017_bb0085","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.thromres.2021.12.017_bb0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.thromres.2021.12.017_bb0100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2021.12.017_bb0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc3978","article-title":"Sympathetic nervous system regulation of the tumour microenvironment","volume":"15","author":"Cole","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.thromres.2021.12.017_bb0110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.thromres.2021.12.017_bb0115","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the","volume":"Eur. J. Heart Fail.","author":"Boer","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.seminoncol.2019.10.006","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology","volume":"46","author":"Yeh","year":"2019","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0125","doi-asserted-by":"crossref","first-page":"28982","DOI":"10.3402\/jchimp.v5.28982","article-title":"Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy","volume":"5","author":"Meseeha","year":"2015","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"issue":"7","key":"10.1016\/j.thromres.2021.12.017_bb0130","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens","volume":"9","author":"Braverman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.thromres.2021.12.017_bb0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.thromres.2021.12.017_bb0140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.thromres.2021.12.017_bb0145","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"Metra","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2021.12.017_bb0150","article-title":"Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data","author":"Hu","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","article-title":"Anticancer treatment and thrombosis","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb. Res."},{"issue":"14","key":"10.1016\/j.thromres.2021.12.017_bb0160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2021.12.017_bb0165","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2021.12.017_bb0170","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0049-3848(20)30391-1","article-title":"An overview of thrombotic complications of old and new anticancer drugs","volume":"191","author":"Levi","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2021.12.017_bb0175","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.2147\/DDDT.S211907","article-title":"Molecular requirements for the expression of antiplatelet effects by synthetic structural optimized analogues of the anticancer drugs imatinib and nilotinib","volume":"13","author":"Pantazi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"23","key":"10.1016\/j.thromres.2021.12.017_bb0180","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.thromres.2021.12.017_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0190","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH","volume":"18","author":"Zwicker","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2021.12.017_bb0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000073282","article-title":"Thalidomide and thrombosis","volume":"33","author":"Rodeghiero","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma","volume":"99","author":"Li","year":"2020","journal-title":"Ann. Haematol."},{"issue":"20","key":"10.1016\/j.thromres.2021.12.017_bb0205","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1042\/CS20160246","article-title":"Molecular mechanisms for vascular complications of targeted cancer therapies","volume":"130","author":"Gopal","year":"2016","journal-title":"Clin. Sci."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2008.09.007","article-title":"Effects of hormonal treatment on lipids in patients with cancer","volume":"35","author":"Filippatos","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.thromres.2021.12.017_bb0215","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2021.12.017_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","article-title":"Thrombotic risk from chemotherapy and other cancer therapies","volume":"179","author":"Jiang","year":"2019","journal-title":"Cancer Treat. Res."},{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0225","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.thromres.2021.12.017_bb0230","article-title":"Paclitaxel induced acute ST elevation myocardial infarction: a rare case report","volume":"10","author":"Rawal","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"issue":"10","key":"10.1016\/j.thromres.2021.12.017_bb0235","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5551\/jat.RV17027","article-title":"Mechanism and management of cancer chemotherapy-induced atherosclerosis","volume":"25","author":"Mukai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00228-013-1598-1","article-title":"Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis","volume":"70","author":"Wang","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0245","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ejhf.2079","article-title":"Arrhythmias in cancer: rhythm is gonna get you!","volume":"23","author":"Farmakis","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"15","key":"10.1016\/j.thromres.2021.12.017_bb0250","first-page":"117","article-title":"A reassessment of cardiac toxicity associated with Taxol","author":"Arbuck","year":"1993","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"8","key":"10.1016\/j.thromres.2021.12.017_bb0255","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/cdd.2012.11","article-title":"Thromboxane A2 modulates cisplatin-induced apoptosis through a Siva1-dependent mechanism","volume":"19","author":"Iorio-Morin","year":"2012","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.thromres.2021.12.017_bb0260","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.jacc.2004.08.053","article-title":"Drug-induced atrial fibrillation","volume":"44","author":"van der Hooft","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2021.12.017_bb0265","first-page":"540","article-title":"Atrial fibrillation following treatment with paclitaxel: a case report","volume":"9","author":"Zhao","year":"2018","journal-title":"Biomed. Rep."},{"issue":"12","key":"10.1016\/j.thromres.2021.12.017_bb0270","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2165\/11633140-000000000-00000","article-title":"Drug-induced atrial fibrillation","volume":"72","author":"Kaakeh","year":"2012","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.thromres.2021.12.017_bb0275","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ejhf.1172","article-title":"Anthracycline-induced cardiomyopathy: secrets and lies","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.thromres.2021.12.017_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.05.016","article-title":"Cardiac dysfunction caused by osimertinib","volume":"12","author":"Oyakawa","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.thromres.2021.12.017_bb0285","doi-asserted-by":"crossref","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of contemporary anticancer immunotherapy","volume":"22","author":"Dal\u2019Bo","year":"2020","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"18","key":"10.1016\/j.thromres.2021.12.017_bb0290","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2021.12.017_bb0295","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1225-6","article-title":"Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management","volume":"21","author":"Ala","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.thromres.2021.12.017_bb0300","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/ars.2009.2598","article-title":"Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging","volume":"12","author":"Terman","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.thromres.2021.12.017_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3579143","article-title":"Oxidative stress in radiation-induced cardiotoxicity","volume":"2020","author":"Ping","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0310","first-page":"15","article-title":"Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment","volume":"11","author":"Cai","year":"2019","journal-title":"Mol. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.thromres.2021.12.017_bb0315","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.thromres.2021.12.017_bb0320","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/1389450116666150304103517","article-title":"Nitroso-redox balance and modulation of basal myocardial function: an update from the Italian Society of Cardiovascular Research (SIRC)","volume":"16","author":"Tocchetti","year":"2015","journal-title":"Curr. Drug Targets"},{"issue":"4","key":"10.1016\/j.thromres.2021.12.017_bb0325","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s11239-020-02313-2","article-title":"Mitochondria and chronic effects of cancer therapeutics: the clinical implications","volume":"51","author":"Dominic","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"issue":"Pt 2","key":"10.1016\/j.thromres.2021.12.017_bb0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1042\/BST0340232","article-title":"Calcium, mitochondria and reperfusion injury: a pore way to die","volume":"34","author":"Halestrap","year":"2006","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0335","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Sim\u016fnek","year":"2009","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0340","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0345","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cmet.2013.07.006","article-title":"Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum","volume":"18","author":"Murphy","year":"2013","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bmb.20244","article-title":"DNA topology and topoisomerases","volume":"37","author":"Deweese","year":"2009","journal-title":"Biochem. Mol. Biol. Educ."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0360","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/15548627.2017.1345412","article-title":"Inflammatory signaling cascades and autophagy in cancer","volume":"14","author":"Monkkonen","year":"2018","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.thromres.2021.12.017_bb0365","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/cgt.2017.4","article-title":"Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin-induced cardiotoxicity","volume":"24","author":"Pop-Moldovan","year":"2017","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0370","doi-asserted-by":"crossref","DOI":"10.1186\/s40959-016-0010-6","article-title":"Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents","volume":"2","author":"Morbidelli","year":"2016","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.thromres.2021.12.017_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on anticancer therapy-mediated vascular toxicity and new horizons in therapeutic strategies","volume":"8","author":"Hsu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0380","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0385","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00498254.2014.942809","article-title":"A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine","volume":"45","author":"Eskandari","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.thromres.2021.12.017_bb0390","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lfs.2017.05.003","article-title":"Polyphenols, autophagy and doxorubicin-induced cardiotoxicity","volume":"180","author":"Shabalala","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.thromres.2021.12.017_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2019.152238","article-title":"Pyrroloquinoline quinine ameliorates doxorubicin-induced autophagy-dependent apoptosis via lysosomal-mitochondrial axis in vascular endothelial cells","volume":"425","author":"Jiang","year":"2019","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.thromres.2021.12.017_bb0400","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bcp.2012.10.005","article-title":"Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity","volume":"85","author":"Sishi","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.thromres.2021.12.017_bb0405","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0410","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"15","key":"10.1016\/j.thromres.2021.12.017_bb0415","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1089\/ars.2020.8019","article-title":"Signaling pathways underlying anthracycline cardiotoxicity","volume":"32","author":"Sala","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.thromres.2021.12.017_bb0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.thromres.2021.12.017_bb0425","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcp.2019.03.038","article-title":"Distinct contribution of Rac1 expression in cardiomyocytes to anthracycline-induced cardiac injury","volume":"164","author":"Henninger","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.thromres.2021.12.017_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040395","article-title":"Perturbation of microRNAs in rat heart during chronic doxorubicin treatment","volume":"7","author":"Vacchi-Suzzi","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.thromres.2021.12.017_bb0435","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: structure, function, and clinical significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.thromres.2021.12.017_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188355","article-title":"HERG channel and cancer: a mechanistic review of carcinogenic processes and therapeutic potential","volume":"1873","author":"He","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821005764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821005764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:24Z","timestamp":1758736044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821005764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":88,"alternative-id":["S0049384821005764"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.12.017","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}